Risk factors and prevention of dabigatran-related gastrointestinal bleeding in patients with atrial fibrillation
| Autor: | Suthipong Soontrapa, Saranapoom Klomjit, Selcuk Adabag, Alejandro Perez-Verdia, Teerapat Nantsupawat, Nopakoon Nantsupawat, David Sotello |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
medicine.medical_specialty
Gastrointestinal bleeding HAS‐BLED gastrointestinal bleeding 030204 cardiovascular system & hematology Dabigatran 03 medical and health sciences 0302 clinical medicine Internal medicine medicine atrial fibrillation dabigatran 030212 general & internal medicine Stroke HAS-BLED business.industry Warfarin Retrospective cohort study Original Articles Odds ratio medicine.disease Cohort Original Article Cardiology and Cardiovascular Medicine business medicine.drug |
| Zdroj: | Journal of Arrhythmia |
| ISSN: | 1880-4276 |
| DOI: | 10.1002/joa3.12015 |
| Popis: | Introduction Dabigatran, as compared with warfarin, was associated with lower rates of stroke and systemic embolism with similar rates of major hemorrhage. But it has a significantly higher risk of gastrointestinal bleeding (GIB). There are limited data on how to prevent GIB from dabigatran and what are the risk factors. Methods We performed a retrospective cohort study of patients with atrial fibrillation who have ever taken dabigatran for thromboprophylaxis from October 2010 to February 2013. Results A total of 247 patients were identified. There were 10 (4%) patients who developed GIB (6 (6.5%) in PPI/H2RA users vs 4 (2.6%) in non‐PPI/H2RA users; P = .184). History of GIB within 1 year prior to dabigatran initiation and HAS‐BLED score ≥3 are independent risk factors for GIB, with odds ratio of 25.14 (95% CI, 2.85‐221.47; P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text